BIO Financials Bio-Rad Laboratories, Inc.

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Aug 9, 2026, 10:13 UTC Overview →

Growth & profitability

Revenue has grown 0.3% per year over the past 5 years.
Net income has grown slower than revenue (-27.6% vs 0.3% per year).
Operating margin has contracted, at 1.8% in the latest year.
Free cash flow has declined 4.7% per year over the past 5 years.

Financial health

Total debt ($1.2B) exceeds cash ($530M); net debt is $673M.
Total debt has grown faster than revenue (150.2% vs 0.3% per year).
Operating income covered interest expense 1.0× in the latest year, down from 19× 5 years ago.
Total debt is 5.7× EBITDA.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
2025	$2.6B	$760M	51.9%	1.8%	10.2%	7.2%	$375M	$1.2B	$530M
2024	$2.6B	-$1.8B	53.7%	10.5%	-28.1%	-19.7%	$290M	$1.2B	$488M
2023	$2.7B	-$637M	53.4%	12.6%	-7.3%	-5.2%	$218M	$1.2B	$404M
2022	$2.8B	-$3.6B	55.9%	17.2%	-37.7%	-26.9%	$82M	$1.2B	$434M
2021	$2.9B	$4.3B	56.1%	17.1%	31.1%	23.9%	$536M	$11M	$471M
2020	$2.5B	$3.8B	56.5%	16.6%	38.6%	29.4%	$476M	$12M	$662M
2019	$2.3B	$1.8B	54.4%	9.9%	30.5%	22.0%	$359M	$14M	$661M
2018	$2.3B	$366M	53.4%	-4.5%	9.1%	6.5%	$156M	$439M	$432M
2017	$2.2B	$122M	55.0%	5.5%	4.2%	2.9%	-$7M	—	$384M
2016	$2.1B	$26M	55.0%	2.7%	1.0%	0.7%	$75M	—	$456M
2015	—	$109M	—	—	4.4%	2.9%	$74M	—	$458M
2014	—	$89M	—	—	4.1%	2.7%	$152M	—	$413M
2013	—	$78M	—	—	3.6%	2.3%	$62M	$436M	$332M
2012	—	$165M	—	—	8.2%	4.8%	$124M	$733M	$463M
2011	—	$179M	—	—	10.3%	5.8%	$160M	$732M	$574M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
Jun '26	$651M	$371M	53.1%	11.2%	5.2%	3.6%	$67M	$1.2B	$517M
Mar '26	$592M	-$527M	52.3%	5.8%	-7.7%	-5.4%	$78M	$1.2B	$507M
Dec '25	$693M	$720M	49.8%	-17.2%	9.7%	6.8%	$119M	$1.2B	$530M
Sep '25	$653M	-$342M	52.6%	10.0%	-5.1%	-3.5%	$89M	$1.2B	$396M
Jun '25	$652M	$318M	53.0%	11.8%	4.5%	3.1%	$71M	$1.2B	$369M
Mar '25	$585M	$64M	52.3%	4.0%	1.0%	0.7%	$96M	$1.2B	$521M
Dec '24	$668M	-$716M	51.2%	8.7%	-10.9%	-7.6%	$81M	$1.2B	$488M
Sep '24	$650M	$653M	54.8%	9.9%	8.7%	6.2%	$123M	$1.2B	$410M
Jun '24	$639M	-$2.2B	55.6%	15.9%	-31.9%	-22.4%	$55M	$1.2B	$407M
Mar '24	$611M	$384M	53.4%	7.3%	4.2%	3.0%	$30M	$1.2B	$433M
Dec '23	$681M	$350M	53.8%	14.0%	4.0%	2.8%	$39M	$1.2B	$404M
Sep '23	$632M	$106M	53.1%	14.4%	1.3%	0.9%	$54M	$1.2B	$458M
Jun '23	$681M	-$1.2B	53.2%	13.2%	-13.8%	-9.7%	$63M	$1.2B	$390M
Mar '23	$677M	$69M	53.5%	9.1%	0.7%	0.5%	$62M	$1.2B	$464M
Dec '22	$730M	$828M	54.4%	16.3%	8.6%	6.1%	$45M	$1.2B	$434M
Sep '22	$681M	-$163M	54.7%	13.9%	-1.9%	-1.4%	-$17M	$1.2B	$518M
Jun '22	$691M	-$925M	57.2%	17.8%	-10.3%	-7.3%	$36M	$1.2B	$597M
Mar '22	$700M	-$3.4B	57.5%	20.9%	-33.0%	-23.4%	$17M	$1.2B	$802M
Dec '21	$733M	-$1.6B	54.6%	16.1%	-11.5%	-8.8%	$115M	$11M	$471M
Sep '21	$747M	$3.9B	58.4%	21.0%	25.6%	19.7%	$196M	$11M	$860M

Valuation over time

How the market has priced BIO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has risen from 10.7× (Dec '25) to 12.9× (Nov '26).
The price-to-sales ratio has fallen from 4.6× (Mar '23) to 3.8× (Nov '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Frequently asked questions

Is BIO growing its revenue and profit?

Over the past 5 years, Bio-Rad Laboratories, Inc.'s revenue has grown 0.3% per year, and net income declined 27.6% per year. These are computed facts, not advice.

How much debt does BIO have?

As of FY2025, Bio-Rad Laboratories, Inc. reported $1.2B of total debt against $530M of cash; operating income covered interest expense 1.0×.

What is BIO's profit margin?

In FY2025, gross margin was 51.9%, operating margin 1.8%, and net margin 29.4%.

What is BIO's P/E ratio?

Bio-Rad Laboratories, Inc.'s P/E (TTM) is 44.03 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the BIO stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 12.9× as of Nov '26) can differ. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.